Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,975 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Carcinoma of Breast Clear all
Completed Not applicable Interventional

The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors

NCT02510430
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Re-Patterning Sitting Time Group, Reducing Sitting Time Group, Usual Care
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00004900
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 28, 2026, 11:19 AM EDT
Recruiting Not applicable Interventional

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

NCT05327608
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration
Other · Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Not applicable Interventional

Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors

NCT01694225
View directory record Official record
Conditions
Breast Cancer
Interventions
bubble packaging for monthly prescription
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 28, 2026, 11:19 AM EDT
Recruiting Not applicable Interventional

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

NCT06085833
View directory record Official record
Conditions
Breast Cancer
Interventions
Nanomechanical Phenotype Test
Diagnostic Test
Lead sponsor
ARTIDIS AG
Industry
Eligibility
18 Years and older
Enrollment
2,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 11:19 AM EDT
Not listed Not applicable Interventional

Acupressure for Cancer-Related Fatigue

NCT03091647
View directory record Official record
Conditions
Breast Cancer
Interventions
acupressure intervention, usual care
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
21 Years to 74 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Results available

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

NCT03364348
View directory record Official record
Conditions
HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Utomilumab, Trastuzumab, Ado-Trastuzumab Emtansine
Drug
Lead sponsor
George W. Sledge Jr.
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 28, 2026, 11:19 AM EDT
Not listed Not applicable Interventional

A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.

NCT01792726
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Boost to the tumour bed
Radiation
Lead sponsor
University College, London
Other
Eligibility
Female only
Enrollment
1,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Savannah, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Not applicable Interventional

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

NCT02192333
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor, Depression, Fatigue, Leukemia, Lymphoma, Malignant Bone Neoplasm, Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Pain, Sleep Disorder, Soft Tissue Sarcoma
Interventions
Management of Therapy Complications, Quality-of-Life Assessment, Questionnaire Administration, Telephone-Based Intervention
Procedure · Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Phase 1 Interventional

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00003548
View directory record Official record
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 28, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional Results available

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Cancer
Interventions
AZD8931, anastrozole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast

NCT00496808
View directory record Official record
Conditions
Ductal Carcinoma In Situ
Interventions
Herceptin (Trastuzumab)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 28, 2026, 11:19 AM EDT
Recruiting Phase 3 Interventional

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3,960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1226
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 809 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00006032
View directory record Official record
Conditions
Breast Cancer
Interventions
etoposide, ifosfamide, topotecan hydrochloride, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

NCT02280252
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Radiation therapy
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 28, 2026, 11:19 AM EDT
Not listed Phase 2 Interventional

ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

NCT00404404
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
Premiere Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 28, 2026, 11:19 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

NCT05069038
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib 125mg
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients

NCT01723943
View directory record Official record
Conditions
Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Psychosocial Effects of Cancer and Its Treatment, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
educational intervention, counseling intervention, psychosocial support for caregiver
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 28, 2026, 11:19 AM EDT
Terminated Phase 1 Interventional

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Not applicable Interventional Results available

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds

NCT03960463
View directory record Official record
Conditions
Surgical Wound, Diabetes, Amputation Wound, Incision Wound, Peripheral Arterial Disease, Breast Cancer, Diabetic Foot
Interventions
Transcu O2®
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Not applicable Interventional

E-Health Support Program (PACK Health Program) in Supporting Patient Reported Symptoms in Newly Diagnosed Patients With Breast Cancer

NCT05549687
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Questionnaire Administration, Supportive Care
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 28, 2026, 11:19 AM EDT
Withdrawn Phase 1 Interventional

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer

NCT00074139
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 69 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 28, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

NCT00136539
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Adriamycin, Cytoxan
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 28, 2026, 11:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

NCT06934239
View directory record Official record
Conditions
Breast Cancer Screening, Artificial Intelligence (AI)
Interventions
Artificial intelligence (AI) decision-support tool
Device
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 28, 2026, 11:19 AM EDT